Small molecule · Agonist · developed by United Therap
Treprostinil is a prostacyclin mimetic that acts on the prostacyclin pathway to cause direct vasodilation of pulmonary and systemic arterial beds and to inhibit platelet aggregation.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 2, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05203510 | Phase 4 | Pulmonary Arterial Hypertension | Active not recruiting | UTHR |
| NCT07285655 | Phase 3 | Pulmonary Hypertension Due to Lung Disease (Disorder) | Recruiting | LQDA |
| NCT05943535 | Phase 3 | Progressive Pulmonary Fibrosis | Recruiting | UTHR |
| NCT03794583 | Phase 3 | Pulmonary Hypertension | Terminated | UTHR |
| NCT07037836 | Phase 2 | COPD (Chronic Obstructive Pulmonary Disease) | Recruiting | UTHR |
| NCT04005469 | Phase 1/2 | Ischemia Reperfusion Injury | Recruiting | UTHR |
| NCT03464864 | Phase 1 | Pulmonary Arterial Hypertension | Completed | MNKD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
COPD (Chronic Obstructive Pulmonary Disease)HypoxemiaInterstitial Lung DiseaseProgressive Pulmonary FibrosisPulmonary Hypertension Due to Lung Disease (Disorder)Chronic Obstructive Pulmonary DiseasePulmonary Arterial HypertensionPulmonary Hypertension
Updated Nov 1, 2026. Something wrong or missing? Report it on the UTHR page.
See UTHR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
UTHR catalysts and pipeline →